|
Market Closed -
Toronto S.E.
12:21:34 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 8.800 CAD | +3.77% |
|
+2.33% | +3.29% |
| 09-17 | COSCIENS Biopharma Raises $4.4 Million Via Second Tranche of Convertible Debenture Offering | MT |
| 09-10 | COSCIENS Biopharma Acquires Pharma Tech Business Nualtis For $15 Million Cash | MT |
Company Valuation: COSCIENS Biopharma Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 26.56 | 43.65 | 15.43 | 9.45 | 4.81 | 6.594 |
| Change | - | 64.32% | -64.65% | -38.75% | -49.1% | 37.08% |
| Enterprise Value (EV) 1 | 2.476 | -21.49 | -35 | -24.29 | -9.273 | 1.436 |
| Change | - | -968.11% | -62.87% | 30.62% | 61.82% | 115.48% |
| P/E | -3.4x | -4.94x | -0.68x | -0.57x | -0.45x | -0.63x |
| PBR | 2.01x | 0.82x | 0.43x | 0.52x | 0.64x | 1.72x |
| PEG | - | 0.1x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | 7.27x | 8.3x | 2.74x | 2.1x | 0.5x | 0.88x |
| EV / Revenue | 0.68x | -4.09x | -6.21x | -5.4x | -0.97x | 0.19x |
| EV / EBITDA | -0.42x | 2.49x | 2.28x | 1.35x | 1.07x | -0.15x |
| EV / EBIT | -0.42x | 2.48x | 2.28x | 1.35x | 0.93x | -0.14x |
| EV / FCF | -0.74x | 4.52x | 3.89x | 2.38x | 3.79x | -0.23x |
| FCF Yield | -136% | 22.1% | 25.7% | 42% | 26.4% | -440% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -37.37 | -21.84 | -56.16 | -40.9 | -17.79 | -9.817 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3.652 | 5.26 | 5.64 | 4.498 | 9.587 | 7.498 |
| EBITDA 1 | -5.896 | -8.646 | -15.36 | -17.99 | -8.678 | -9.515 |
| EBIT 1 | -5.925 | -8.671 | -15.38 | -18.01 | -9.942 | -10.44 |
| Net income 1 | -5.118 | -8.368 | -22.73 | -16.55 | -15.31 | -10.36 |
| Net Debt 1 | -24.09 | -65.14 | -50.43 | -33.74 | -14.08 | -5.158 |
| Reference price 2 | 127.138 | 107.863 | 38.125 | 23.352 | 8.048 | 6.214 |
| Nbr of stocks (in thousands) | 209 | 405 | 405 | 405 | 598 | 1,061 |
| Announcement Date | 3/24/21 | 3/28/22 | 3/23/23 | 3/27/24 | 4/9/25 | 3/25/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.02M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 26.88x | 26.33x | 15.57x | 0.34% | 38.04B | |
| Weighted average by Cap. | 26.55x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CSCI Stock
- Valuation COSCIENS Biopharma Inc.
Select your edition
All financial news and data tailored to specific country editions
